ECCO溃疡性结肠炎最新治疗指南解读

解莹; 田丰

doi:10.3969/j.issn.1671-038X.2024.08.11

ECCO溃疡性结肠炎最新治疗指南解读

解莹¹,
田丰^1, ,

- 中国医科大学附属盛京医院消化内科(沈阳，110004)
基金项目:
辽宁省科技厅博士科研启动基金计划项目(No：2022-BS-127)

详细信息

通讯作者: 田丰，E-mail：tianfeng@sj-hospital.org

中图分类号: R259

收稿日期: 2024-05-23

刊出日期: 2024-08-15

Introduction of the latest ECCO Guidelines on therapeutics in ulcerative colitis

XIE Ying¹,
TIAN Feng^1, ,

- Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, 110004, China

More Information

Corresponding author: TIAN Feng, E-mail: tianfeng@sj-hospital.org

Received Date: 23 May 2024

Publish Date: 15 August 2024

摘要

摘要: 炎症性肠病(inflammatory bowel disease，IBD)主要包括溃疡性结肠炎(ulcerative colitis，UC)和克罗恩病(Crohn's disease，CD)。随着对疾病认识的不断加深、新药研发及新的循证医学证据的出现，对于IBD的治疗理念也发生着日新月异的变化。2022年初欧洲克罗恩和结肠炎组织(European Crohn's and Colitis Organisation，ECCO)正式发布了UC治疗指南，分为药物治疗篇和手术治疗篇。本文对照2017版ECCO共识，针对ECCO最新UC治疗指南，结合最新循证医学证据进行解读，以帮助临床医生更好地了解国内外UC治疗的新策略，提高UC的诊疗水平。
- 欧洲克罗恩和结肠炎组织 /
- 溃疡性结肠炎 /
- 治疗指南
Abstract: Inflammatory bowel disease(IBD) mainly includes ulcerative colitis(UC) and Crohn's disease(CD). With the continuous deepening of understanding of IBD, the development of new drugs, and the emergence of new evidence-based medicine, the treatment concepts for IBD are also undergoing rapid changes. In early 2022, the European Crohn's and Colitis Organisation(ECCO) officially published guidelines for the treatment of UC, which including medical treatment and surgical treatment sections. This article compares the 2017 version of the ECCO consensus and interprets the latest UC treatment guidelines, based on the latest evidence-based medicine evidence, in order to help clinicians better understanding the new strategies for UC treatment and improve the level of UC diagnosis and treatment.
- European Crohn' s and Colitis Organisation /
- ulcerative colitis /
- guidelines on therapeutics

HTML全文

参考文献(35)

[1]	Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment[J]. J Crohns Colitis, 2022, 16(1): 2-17. doi: 10.1093/ecco-jcc/jjab178
[2]	Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment[J]. J Crohns Colitis, 2022, 16(2): 179-189. doi: 10.1093/ecco-jcc/jjab177
[3]	中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安)[J]. 中华炎性肠病杂志(中英文), 2024, 8(1): 33-58.
[4]	Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 590-600. doi: 10.1038/ajg.2011.70
[5]	Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis[J]. Gastroenterology, 2014, 146(2): 392-400. e3. doi: 10.1053/j.gastro.2013.10.052
[6]	Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial[J]. Gut, 2020, 69(7): 1206-1212. doi: 10.1136/gutjnl-2019-319758
[7]	Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions[J]. Clin Gastroenterol Hepatol, 2016, 14(3): 348-354. e17. doi: 10.1016/j.cgh.2015.06.001
[8]	Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review[J]. Clin Gastroenterol Hepatol, 2018, 16(3): 343-356. e3. doi: 10.1016/j.cgh.2017.06.016
[9]	Lynch RW, Churchhouse AM, Protheroe A, et al. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using UK IBD audit data[J]. Aliment Pharmacol Ther, 2016, 43(11): 1132-1141. doi: 10.1111/apt.13614
[10]	Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369(8): 699-710. doi: 10.1056/NEJMoa1215734
[11]	Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a Phase 3, randomized, double-blind, placebo-controlled study[J]. PLoS One, 2019, 14(2): e0212989. doi: 10.1371/journal.pone.0212989
[12]	Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium[J]. Am J Gastroenterol, 2018, 113(9): 1345. doi: 10.1038/s41395-018-0162-0
[13]	Narula N, Wong ECL, Marshall JK, et al. Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2022, 20(7): 1588-1597. e3. doi: 10.1016/j.cgh.2021.07.038
[14]	Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis[J]. N Engl J Med, 2012, 367(7): 616-624. doi: 10.1056/NEJMoa1112168
[15]	Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2017, 376(18): 1723-1736. doi: 10.1056/NEJMoa1606910
[16]	Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials[J]. Lancet, 2022, 399(10341): 2113-2128. doi: 10.1016/S0140-6736(22)00581-5
[17]	Sands BE, Sandborn WJ, Panaccione R, et al. UNIFI Study Group. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis[J]. N Engl J Med, 2019, 381(13): 1201-1214. doi: 10.1056/NEJMoa1900750
[18]	Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab[J]. Clin Gastroenterol Hepatol, 2015, 13(3): 522-530. e2. doi: 10.1016/j.cgh.2014.07.029
[19]	Kelly OB, Donnell SO, Stempak JM, et al. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease[J]. Inflamm Bowel Dis, 2017, 23(7): 1202-1209. doi: 10.1097/MIB.0000000000001126
[20]	Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis[J]. N Engl J Med, 2019, 381(13): 1215-1226. doi: 10.1056/NEJMoa1905725
[21]	Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis[J]. Gut, 1996, 38(6): 905-910. doi: 10.1136/gut.38.6.905
[22]	Adams A, Gupta V, Mohsen W, et al. Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response[J]. Gut, 2023, 72(3): 433-442. doi: 10.1136/gutjnl-2022-327533
[23]	Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids[J]. Am J Gastroenterol, 2016, 111(4): 477-491. doi: 10.1038/ajg.2016.7
[24]	Szemes K, Soós A, Hegyi P, et al. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis[J]. Front Med(Lausanne), 2020, 6: 338.
[25]	Williams JG, Alam MF, Alrubaiy L, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis(CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(1): 15-24. doi: 10.1016/S2468-1253(16)30003-6
[26]	Laharie D, Bourreille A, Branche J, et al. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab[J]. Gut, 2018, 67(2): 237-243. doi: 10.1136/gutjnl-2016-313060
[27]	Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up[J]. Aliment Pharmacol Ther, 2007, 26(5): 747-756. doi: 10.1111/j.1365-2036.2007.03415.x
[28]	Sjöberg M, Magnuson A, Björk J, et al. Swedish Organization for the Study of Inflammatory Bowel Disease(SOIBD). Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients[J]. Aliment Pharmacol Ther, 2013, 38(4): 377-387. doi: 10.1111/apt.12387
[29]	Sebastian S, Myers S, Argyriou K, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis[J]. Aliment Pharmacol Ther, 2019, 50(6): 675-683. doi: 10.1111/apt.15456
[30]	Lamb CA, Kennedy NA, Raine T, et al. IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults[J]. Gut, 2019, 68(Suppl 3): s1-s106. doi: 10.1136/gutjnl-2019-318484
[31]	Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis[J]. Inflamm Bowel Dis, 2019, 25(1): 56-66.
[32]	Narula N, Fine M, Colombel JF, et al. Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks?[J]. Inflamm Bowel Dis, 2015, 21(7): 1683-1694. doi: 10.1097/MIB.0000000000000350
[33]	Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2008, 6(10): 1112-1116. doi: 10.1016/j.cgh.2008.04.035
[34]	Berinstein JA, Sheehan JL, Dias M, et al. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2112-2120. e1. doi: 10.1016/j.cgh.2021.05.038
[35]	Uzzan M, Bresteau C, Laharie D, et al. GETAID-TALC Study Group. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort[J]. Aliment Pharmacol Ther, 2021, 54(3): 312-319. doi: 10.1111/apt.16463